US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
France Targets Shein, Temu With Fast-Fashion Fees 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Milei Threatens Falkland Oil Firms With Sanctions 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Add as a preferred source on Google
SEATTLE, March 06, 2018 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the 38th Annual Cowen Healthcare Conference in Boston.
Brad Gray, president and chief executive officer, is scheduled to present on Tuesday, March 13, 2018 at 11:20am ET. Interested parties can access the live webcast with accompanying slides from the investor section of the company’s website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentation and archived for 60 days.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,900 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
NanoString, NanoString Technologies, the NanoString logo, 3D Biology, 3D Flow, nCounter, PanCancer IO360 and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Contact:
Doug Farrell
Vice President, Investor Relations & Corporate Communications
[email protected]
Phone: 206-602-1768
